Xerox Holdings Corporation’s XRX will report second-quarter 2021 results on Jul 27, before the bell.The company has an impressive earnings surprise history. It surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed the same in the other two, delivering an earnings surprise of 29.3%, on average.Expectations This Time AroundThe Zacks Consensus Estimate for revenues in the to-be-reported quarter is pegged at $1.71 billion, indicating growth of 16.8% from the year-ago actual figure. Growth in equipment revenues is expected to have benefited the top line in the quarter.The consensus mark for earnings stands at 43 cents, indicating more than 100% year-over-year growth. Higher revenues and operating performance are likely to have benefited the bottom line in the quarter.What Our Model SaysOur proven Zacks model does not conclusively predict an earnings beat for Xerox this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Xerox has an Earnings ESP of -17.65% and Zacks Rank #5 (Strong Sell).Xerox Holdings Corporation Price and EPS Surprise Xerox Holdings Corporation price-eps-surprise | Xerox Holdings Corporation QuoteStocks That Warrant a LookHere are a few stocks from the broader Zacks Business Services sector that investors may consider, as our model shows that these have the right combination of elements to beat onearnings this season.Visa V has an Earnings ESP of +2.55% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.Global Payments GPN, with an Earnings ESP of +31.78% and carrying a Zacks Rank of 2 as well.Aptiv APTV, which has an Earnings ESP of +0.29% and a Zacks Rank #3. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Visa Inc. (V): Free Stock Analysis Report Xerox Holdings Corporation (XRX): Free Stock Analysis Report Global Payments Inc. (GPN): Free Stock Analysis Report Aptiv PLC (APTV): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research